Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

(2015) L. Karlsson et al.   OSTEOPOROSIS INTERNATIONAL

Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States

(2015) Lung-I Cheng et al.   Journal of Managed Care & Specialty Pharmacy

Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis

(2014) Lesley J. Scott   DRUGS & AGING

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

(2014) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

(2012) Sally W. Wade et al.   BONE

Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database

(2012) Cyrille B Confavreux et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan

(2012) Y.-K. Soong et al.   OSTEOPOROSIS INTERNATIONAL

Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database

(2011) Lin Li et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

(2011) J. Devine et al.   OSTEOPOROSIS INTERNATIONAL

The impact of teriparatide adherence and persistence on fracture outcomes

(2011) S. Yu et al.   OSTEOPOROSIS INTERNATIONAL

Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA)

(2011) E. Landfeldt et al.   OSTEOPOROSIS INTERNATIONAL

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Bone density consequences of initiation and compliance with therapy for osteoporosis

(2010) Robert A. Yood et al.   ARTHRITIS CARE & RESEARCH

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

(2009) F.-E. Cotté et al.   OSTEOPOROSIS INTERNATIONAL

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

(2009) I. Imaz et al.   OSTEOPOROSIS INTERNATIONAL